Alcobra Ltd. (NASDAQ:ADHD) has analysts on the Bullish side this week.

December 7, 2017 - By Marie Mckinney

 Alcobra Ltd. (NASDAQ:ADHD) has analysts on the Bullish side this week.

Alcobra Ltd. (NASDAQ:ADHD) Ratings Coverage

Among 7 analysts covering Alcobra (NASDAQ:ADHD), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Alcobra had 19 analyst reports since August 9, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Friday, August 11 by Roth Capital. Jefferies initiated the stock with “Buy” rating in Thursday, February 18 report. The stock of Alcobra Ltd. (NASDAQ:ADHD) has “Buy” rating given on Thursday, February 4 by Roth Capital. As per Tuesday, June 7, the company rating was initiated by Cantor Fitzgerald. The firm earned “Hold” rating on Wednesday, November 2 by WBB Securities. On Thursday, September 29 the stock rating was downgraded by Cantor Fitzgerald to “Hold”. The stock has “Hold” rating by Zacks on Monday, August 17. The stock of Alcobra Ltd. (NASDAQ:ADHD) earned “Underweight” rating by Barclays Capital on Friday, October 28. The company was upgraded on Monday, October 9 by WBB Securities. On Tuesday, June 21 the stock rating was maintained by Roth Capital with “Buy”. Below is a list of Alcobra Ltd. (NASDAQ:ADHD) latest ratings and price target changes.

09/10/2017 Broker: WBB Securities Old Rating: Hold New Rating: Speculative Buy New Target: $2 Upgrade
29/09/2017 Broker: Roth Capital Rating: Hold New Target: $1.0 Downgrade
11/08/2017 Broker: Roth Capital Rating: Buy New Target: $4.0000 Maintain
12/06/2017 Broker: Jefferies Rating: Hold New Target: $1.2500 Maintain

The stock increased 4.29% or $0.42 during the last trading session, reaching $10.22. About 1.11 million shares traded. Alcobra Ltd. (NASDAQ:ADHD) has declined 74.73% since December 7, 2016 and is downtrending. It has underperformed by 91.43% the S&P500.

More notable recent Alcobra Ltd. (NASDAQ:ADHD) news were published by: which released: “Arcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference” on October 06, 2017, also with their article: “Arcturus Therapeutics and Synthetic Genomics Announce Strategic Alliance to …” published on October 31, 2017, published: “Arcturus Therapeutics Announces Completion of Merger with Alcobra Ltd. and …” on November 16, 2017. More interesting news about Alcobra Ltd. (NASDAQ:ADHD) were released by: and their article: “Alcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge” published on September 27, 2017 as well as‘s news article titled: “BRIEF-Alcobr, Arcturus Therapeutics agree to merge” with publication date: September 27, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: